Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation
Journal of Molecular Cell Biology · 13.06.2023 · 15 (2)
DOI: 10.1093/jmcb/mjad014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Cell Biology, online erschienen am 02.03.2023. Verfasst von Cen Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Development, Beijing Youan hospital, Capital Medical University, Beijing 100069, China. Hauptthemen laut MEDLINE: Hypercholesterolemia, Atherosclerosis, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Beyond glycemic control, applications of glucagon-like peptide-1 receptor (GLP-1r) agonists (GLP-1 RAs) inhibit inflammation and plaque development in murine atherosclerotic models. However, whether they modulate hematopoietic stem/progenitor cells (HSPCs) to prohibit skewed myelopoiesis in hypercholesteremia remains unknown. In this study, GLP-1r expression in fluorescence-activated cell sorting (FACS)-sorted wild-type HSPCs was determined by capillary western blotting. Bone marrow cells (BMCs) of wild-type or GLP-1r−/− mice were transplanted into lethally irradiated low-density lipoprotein receptor deficient (LDLr−/−) recipients followed by high-fat diet (HFD) for chimerism analysis by FACS. In parallel, LDLr−/− mice were placed on HFD for 6 weeks and then treated with saline or Exendin-4 (Ex-4) for another 6 weeks. HSPC frequency and cell cycle were analyzed by FACS, and intracellular metabolite levels were assessed by targeted metabolomics. The results demonstrated that HSPCs expressed GLP-1r and transplantation of GLP-1r−/− BMCs resulted in skewed myelopoiesis in hypercholesterolemic LDLr−/− recipients. In vitro, Ex-4 treatment of FACS-purified HSPCs suppressed cell expansion and granulocyte production induced by LDL. In vivo, Ex-4 treatment inhibited plaque progression, suppressed HSPC proliferation, and modified glycolytic and lipid metabolism in HSPCs of hypercholesteremic LDLr−/− mice. In conclusion, Ex-4 could directly inhibit HSPC proliferation induced by hypercholesteremia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science and Development, Beijing Youan hospital, Capital Medical University, Beijing 100069, China.
- Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
- State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.
- Neuroscience Research Institute, Peking University Center of Medical and Health Analysis, Peking University, Beijing 100191, China.
ORCID-Profile: Guanghou Shui, Yingmei Feng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, C., Ma, X., Lam, S. M., Zhang, Y., Cao, Y., Dong, Y., Su, L., Shui, G., & Feng, Y. (2023). Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation. Journal of Molecular Cell Biology, 15(2). https://doi.org/10.1093/jmcb/mjad014
Vancouver
Yan C, Ma X, Lam SM, Zhang Y, Cao Y, Dong Y, et al. Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation. Journal of Molecular Cell Biology. 2023;15(2). doi:10.1093/jmcb/mjad014
BibTeX
@article{Yan2023,
author = {Yan, Cen and Ma, Xiaojuan and Lam, Sin Man and Zhang, Yuejie and Cao, Yu and Dong, Yuan and Su, Li and Shui, Guanghou and Feng, Yingmei},
title = {Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation},
journal = {Journal of Molecular Cell Biology},
year = {2023},
volume = {15},
number = {2},
doi = {10.1093/jmcb/mjad014}
}
EUVIMED